DaVita, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US23918K1088
USD
117.28
-0.97 (-0.82%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About DaVita, Inc. stock-summary
stock-summary
DaVita, Inc.
Pharmaceuticals & Biotechnology
DaVita Inc., formerly DaVita HealthCare Partners Inc., operates one division: DaVita Kidney Care (Kidney Care). The Kidney Care division consists of the Company's United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support. The Company's segments include U.S. dialysis and related lab services and Other-Ancillary services and strategic initiatives. Its U.S. dialysis and related lab services line of business provide kidney dialysis services in the United States for patients suffering from chronic kidney failure, also known as an end-stage renal disease (ESRD). In addition, as of March 31, 2019, the Company operated or provided administrative services to 243 outpatient dialysis centers located in nine countries outside of the United States.
Company Coordinates stock-summary
Company Details
2000 16th St , DENVER CO : 80202-5158
stock-summary
Tel: 1 310 53626681 310 5362585
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 115 Schemes (20.47%)

Foreign Institutions

Held by 317 Foreign Institutions (11.2%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Ms. Pamela Arway
Independent Chairman of the Board
Mr. Javier Rodriguez
Chief Executive Officer, Director
Mr. Charles Berg
Director
Mr. Shawn Guertin
Director
Ms. Barbara Desoer
Independent Director
Mr. Paul Diaz
Independent Director
Mr. John Nehra
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
3,380 Million
(Quarterly Results - Jun 2025)
Net Profit:
275 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 10,660 Million (Small Cap)

stock-summary
P/E

10.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-26.14

stock-summary
Return on Equity

-296.97%

stock-summary
Price to Book

-28.84